Department of Cardiovascular Sciences


Meet our team


John Cleland - Moderator John Cleland is a Cardiologist and Director of the Robertson Centre for Biostatistics, an internationally accredited Clinical Trials Unit offering a complete service, both to academia and industry, for the conduct of trials and registries in many therapeutic areas. His main interest is heart failure, extending from its epidemiology and prevention, to Phase II-IV trials and the development and implementation of guidelines. Particular current interests include the myocardial substrate, mechanisms of progression (eg. congestion and inflammation), telemonitoring and theranostics.

Ben GibbisonBen Gibbison is Associate Professor of Cardiac Anaesthesia and Intensive Care at the Bristol Heart Institute. His research interests surround Hypothalamic-Pituitary-Adrenal Axis dysfunction and brain dysfunction after cardiac surgery and in critical illness. He also is Chief Investigator for a number of NIHR funded clinical trials.

Health Services Researchers

Rod Taylor - Moderator Rod Taylor is Professor of Population Health Research at University of Glasgow. He has extensive research experience in cardiac rehabilitation and secondary prevention including leadership of the Cochrane Heart Rehabilitation group a number of UK based randomised trails of home-based rehabilitation for people with heart disease including REACH-HF

Maria PufuleteMaria Pufulete is an applied health methodologist at the Bristol Health Institute. She designs and conducts randomised controlled trials, non-randomised studies, systematic reviews and mixed methods studies in cardiovascular disease. She is Chief Investigator for multiple NIHR-funded studies.

Patient and Public Representatives

Jenny CamaradouJenny Camaradou is a legally trained former lobbyist with commercial experience across policy, partnerships, project management and innovation R&D commercialisation of start-ups. She is an alumni of EURORDIS, the voice of Rare Disease patients in Europe and one of 60 trainees from 30 countries chosen in a competitive pharma and IMI sponsored training course on medicines RD and pharmaceutical lifecycle development called EUPATI, training to become a patient expert active participant in both regulatory affairs and clinical trials.

Jenny has undertaken part in various PPI activity for HDRUK, BHF and is a lay member across both NIHR and NICE committees. She holds advisory positions on International Scientific Advisory board of the Advanced Pain Discovery Platform, a joint initiative by the MRC, UKRI and industry funded for £24m and is also a Citizen Scientist appointed to the WG for horizon-scanning group of the COVID19-END Evidence network by McMasterforum and Cochrane. 

Jenny was diagnosed with a genetic condition aged 34 and has had substantial experience as a health service user across different specialisms and surgeries. Hailing from a medical family but with no clinical or scientific background herself, Jenny now has an emerging academic interest in digital engagement and patient centricity in translational research areas and is currently seeking different opportunities to foster co-creation between patients, industry, clinicians, academia working in healthcare provision.

Phil CollisPhil Collis

Phil lives with CVD and is experienced working with patient groups and organisations including British Heart Foundation, European Heart Network, and the National Institute for Health Research. Phil works to ensure people affected by CVD have access to evidence-based information and the opportunity to influence CVD research. Phil also acts as a patient advisor with the Centre for Patient Reported Outcomes Research Centre based at Birmingham University.

Cardiothoracic Interdisciplinary Research Network Representative

Georgia Layton - CIRN representative Georgia Layton is a Cardiothoracic Surgery trainee based within the East Midlands. She has extensive experience within collaborative research networks. She has previously worked closely with the Birmingham Clinical Trials Unit during the early stages of ROSSINI-2; a national, randomised control trial assessing methods for reducing surgical site infection (SSI). Georgia is keen to build upon her experience of surgical collaborations and social media management to promote national engagement from sites around the UK in future trials targeting SSI.

Back to top